Inovio’s (INO) Q4 Loss Narrower than Expected, Revenues Beat – Nasdaq
Nasdaq |
Inovio's (INO) Q4 Loss Narrower than Expected, Revenues Beat
Nasdaq Moreover, the company also received additional $1.2 million revenues under Inovio's prior collaboration with Roche RHHBY for the development of Inovio's DNA immunotherapy, INO-180. However, upside in revenues was partially offset by lower grants … |
